CN116601150A - 稠合双环raf抑制剂及其使用方法 - Google Patents

稠合双环raf抑制剂及其使用方法 Download PDF

Info

Publication number
CN116601150A
CN116601150A CN202180066002.9A CN202180066002A CN116601150A CN 116601150 A CN116601150 A CN 116601150A CN 202180066002 A CN202180066002 A CN 202180066002A CN 116601150 A CN116601150 A CN 116601150A
Authority
CN
China
Prior art keywords
substituted
compound
unsubstituted
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066002.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·贝尔菲尔德
C·D·琼斯
J-F·玛格特
C·科莱托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of CN116601150A publication Critical patent/CN116601150A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180066002.9A 2020-07-28 2021-07-28 稠合双环raf抑制剂及其使用方法 Pending CN116601150A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063057536P 2020-07-28 2020-07-28
US63/057536 2020-07-28
PCT/EP2021/071212 WO2022023447A2 (en) 2020-07-28 2021-07-28 Fused bicyclic raf inhibitors and methods for use thereof

Publications (1)

Publication Number Publication Date
CN116601150A true CN116601150A (zh) 2023-08-15

Family

ID=77499800

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066002.9A Pending CN116601150A (zh) 2020-07-28 2021-07-28 稠合双环raf抑制剂及其使用方法

Country Status (11)

Country Link
US (3) US11858930B2 (cg-RX-API-DMAC7.html)
EP (1) EP4188552A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023535790A (cg-RX-API-DMAC7.html)
KR (1) KR20230058399A (cg-RX-API-DMAC7.html)
CN (1) CN116601150A (cg-RX-API-DMAC7.html)
AU (1) AU2021314955A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001557A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187514A1 (cg-RX-API-DMAC7.html)
IL (1) IL300113A (cg-RX-API-DMAC7.html)
MX (1) MX2023001275A (cg-RX-API-DMAC7.html)
WO (1) WO2022023447A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11858930B2 (en) 2020-07-28 2024-01-02 Jazz Pharmaceuticals Ireland Limited Fused bicyclic RAF inhibitors and methods for use thereof
CN116143633B (zh) * 2022-12-30 2026-05-26 浙江巍华新材料股份有限公司 一种制备2,5-二氯-4-三氟甲基苯胺的方法
US20260232643A1 (en) * 2023-02-17 2026-08-13 Jazz Pharmaceuticals Ireland Limited Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations
WO2024210578A1 (ko) * 2023-04-05 2024-10-10 주식회사 바오밥에이바이오 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743242A (zh) * 2007-06-29 2010-06-16 苏尼西斯制药有限公司 用作raf激酶抑制剂的杂环化合物
CN107108588A (zh) * 2014-09-12 2017-08-29 莱德克斯制药公共有限公司 可用于治疗癌症的稠合双环(杂)芳香族化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932657A (en) 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
JPS6058915A (ja) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPH0617309B2 (ja) 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
DE3611229A1 (de) 1986-04-04 1987-10-08 Basf Ag Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5698550A (en) 1993-06-14 1997-12-16 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
JP2930421B2 (ja) 1994-02-28 1999-08-03 メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤組成物、その製造方法及びその使用方法
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8137699B2 (en) 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
FI20011507A0 (fi) 2001-07-10 2001-07-10 Orion Corp Uusia yhdisteitä
EP1432403B1 (en) 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20050118250A1 (en) 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
CN1690056A (zh) 2004-04-30 2005-11-02 北京大学 三个化合物及其制备方法和用途
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007067444A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
WO2008009079A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
DK2797888T3 (en) 2011-12-31 2016-09-19 Beigene Ltd Fused tricyclic compounds as RAF kinase inhibitors
CN109503659B (zh) 2019-01-03 2021-06-18 凯特立斯(深圳)科技有限公司 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用
IL300110A (en) 2020-07-28 2023-03-01 Jazz Pharmaceuticals Ireland Ltd Chiral synthesis of fused bicyclic raf inhibitors
US11858930B2 (en) 2020-07-28 2024-01-02 Jazz Pharmaceuticals Ireland Limited Fused bicyclic RAF inhibitors and methods for use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743242A (zh) * 2007-06-29 2010-06-16 苏尼西斯制药有限公司 用作raf激酶抑制剂的杂环化合物
CN107108588A (zh) * 2014-09-12 2017-08-29 莱德克斯制药公共有限公司 可用于治疗癌症的稠合双环(杂)芳香族化合物

Also Published As

Publication number Publication date
WO2022023447A3 (en) 2022-03-10
US20220033398A1 (en) 2022-02-03
US20260092063A1 (en) 2026-04-02
EP4188552A2 (en) 2023-06-07
JP2023535790A (ja) 2023-08-21
IL300113A (en) 2023-03-01
CA3187514A1 (en) 2022-02-03
KR20230058399A (ko) 2023-05-03
BR112023001557A2 (pt) 2023-04-04
AU2021314955A1 (en) 2023-03-30
MX2023001275A (es) 2023-04-24
US11858930B2 (en) 2024-01-02
WO2022023447A2 (en) 2022-02-03
US20240124452A1 (en) 2024-04-18
US12304912B2 (en) 2025-05-20

Similar Documents

Publication Publication Date Title
AU2019378184B2 (en) 2,3-dihydro-1H-pyrrolo(3,4-c)pyridin-1-one derivatives as HPK1 inhibitors for the treatment of cancer
AU2019249849B2 (en) BRM targeting compounds and associated methods of use
AU2019382504B2 (en) Cyclic ureas
IL323675A (en) FGFR inhibitors and methods of using them
CN112707893B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
EP4295852A2 (en) Piperidine derivatives as inhibitors of cyclin dependent kinase 7 (cdk7)
EP4153582B1 (en) Piperazine cyclic ureas
CN118286225A (zh) 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
US12304912B2 (en) Fused bicyclic RAF inhibitors and methods for use thereof
CN114144230B (zh) 作为eed和prc2调节剂的大环唑并吡啶衍生物
CN107108588B (zh) 可用于治疗癌症的稠合双环(杂)芳香族化合物
AU2013272701A1 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
AU2021265578B2 (en) Azalactam compounds as HPK1 inhibitors
CN117836296A (zh) 吡唑并吡啶酮化合物
WO2021224818A1 (en) Isoindolone compounds as hpk1 inhibitors
TW202140499A (zh) 巨環rip2-激酶抑制劑
US20240398811A1 (en) Prc2 inhibitors for use in treating blood disorders
WO2025062334A1 (en) 4-((5-(3-(4-(pyridin-2-yl)cyclopentyl)-1 h-pyrazol-3-yl)amino)-benzenesulfonamide derivatives and similar compounds as cdk inhibitors for the treatment of cancer
AU2023345059A1 (en) Cyclin-dependent kinase 7 inhibitors
OA20310A (en) 2,3-dihydro-1H-pyrrolo[3,4-C] pyridin-1one derivatives as HPK1 inhibitors for the treatment of cancer.
EA044841B1 (ru) ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ПИРРОЛО[3,4-с]ПИРИДИН-1-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ HPK1 ДЛЯ ЛЕЧЕНИЯ РАКА

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination